1Department of Clinical Pharmacy, India
2Sri Bhadrakali Diabetic Clinic, India
*Corresponding author:Bandaru SSB, Department of Clinical Pharmacy, Vaagdevi College of Pharmacy, Warangal, India; Email: firstname.lastname@example.org
Submission: April 12, 2018; Published: May 04, 2018
ISSN : 2576-8816Volume5 Issue1
Diabetic Peripheral neuropathy [DPN] is a major long term problem allied with diabetes that can cause serious disability and also death. It is caused by damage to any nerve in the peripheral nervous system. Fifty to seventy five percent of all ulcerations and non trauma amputations are a consequence of diabetic neuropathy. Epalrestat and Pregabalin are widely used to overcome neuronal damage. This study was designed to evaluate the efficacy of these two drug regimens.
Material and methods: Patients included in this study were experiencing pain because of diabetic neuropathy for at least 6months to 2 years.
Results: From 256 subjects with diabetic neuropathy included in the study, 229 patients concluded final analysis. 27 patients dropped from the study (17and 10 patients from pregabalin and epalrestat respectively). Mean pain score was reduced from 5.08±0.82 (severe pain) at first visit to 3.43±0.93 (moderate pain) in the epalrestat group, from 6.42±1.01 (severe pain) at first visit to 2.57±0.59 (mild pain) in the pregabalin group.
Conclusion: We conclude that pregabalin was significantly more effective than epalrestat in controlling pain in DPN patients.
Keywords: Diabetic peripheral neuropathy; Epalrestat and pregabalin